Insufficient scRNA-seq data for expression of PELI3 at single-cell level.
Insufficient scRNA-seq data for expression of PELI3 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 100% | 1634.67 | 245 / 245 | 100% | 18.05 | 502 / 502 |
brain | 100% | 2465.43 | 2639 / 2642 | 100% | 16.70 | 703 / 705 |
adrenal gland | 100% | 1046.12 | 258 / 258 | 100% | 18.17 | 229 / 230 |
ovary | 100% | 1411.35 | 180 / 180 | 99% | 10.18 | 427 / 430 |
uterus | 100% | 1651.62 | 170 / 170 | 99% | 10.18 | 455 / 459 |
breast | 100% | 923.09 | 459 / 459 | 99% | 12.35 | 1108 / 1118 |
thymus | 99% | 733.68 | 649 / 653 | 100% | 9.49 | 602 / 605 |
skin | 99% | 723.85 | 1782 / 1809 | 100% | 10.65 | 470 / 472 |
bladder | 100% | 1599.24 | 21 / 21 | 98% | 8.66 | 494 / 504 |
kidney | 98% | 563.06 | 87 / 89 | 100% | 10.10 | 898 / 901 |
lung | 97% | 634.97 | 562 / 578 | 99% | 8.97 | 1141 / 1155 |
esophagus | 99% | 1406.97 | 1432 / 1445 | 97% | 8.41 | 177 / 183 |
stomach | 97% | 849.60 | 350 / 359 | 94% | 6.15 | 268 / 286 |
intestine | 96% | 1152.55 | 930 / 966 | 94% | 5.52 | 494 / 527 |
pancreas | 91% | 432.51 | 297 / 328 | 99% | 11.10 | 177 / 178 |
liver | 37% | 126.73 | 84 / 226 | 82% | 4.75 | 331 / 406 |
eye | 0% | 0 | 0 / 0 | 100% | 17.90 | 80 / 80 |
tonsil | 0% | 0 | 0 / 0 | 100% | 9.78 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 5.23 | 1 / 1 |
blood vessel | 100% | 1373.73 | 1334 / 1335 | 0% | 0 | 0 / 0 |
muscle | 99% | 1236.55 | 797 / 803 | 0% | 0 | 0 / 0 |
adipose | 99% | 810.77 | 1192 / 1204 | 0% | 0 | 0 / 0 |
spleen | 98% | 539.64 | 237 / 241 | 0% | 0 | 0 / 0 |
heart | 92% | 566.47 | 791 / 861 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 90% | 3.14 | 26 / 29 |
peripheral blood | 53% | 253.52 | 488 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0008592 | Biological process | regulation of Toll signaling pathway |
GO_0010804 | Biological process | negative regulation of tumor necrosis factor-mediated signaling pathway |
GO_0070534 | Biological process | protein K63-linked ubiquitination |
GO_0045087 | Biological process | innate immune response |
GO_2001237 | Biological process | negative regulation of extrinsic apoptotic signaling pathway |
GO_0005829 | Cellular component | cytosol |
GO_0061630 | Molecular function | ubiquitin protein ligase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | PELI3 |
Protein name | Pellino E3 ubiquitin protein ligase family member 3 E3 ubiquitin-protein ligase pellino homolog 3 (Pellino-3) (EC 2.3.2.27) PELI3 protein |
Synonyms | |
Description | FUNCTION: E3 ubiquitin ligase catalyzing the covalent attachment of ubiquitin moieties onto substrate proteins . Involved in the TLR and IL-1 signaling pathways via interaction with the complex containing IRAK kinases and TRAF6 . Mediates 'Lys-63'-linked polyubiquitination of IRAK1 . Can activate AP1/JUN and ELK1 . Acts as a regulator of innate immunity by mediating 'Lys-63'-linked polyubiquitination of RIPK2 downstream of NOD1 and NOD2, thereby transforming RIPK2 into a scaffolding protein for downstream effectors, ultimately leading to activation of the NF-kappa-B and MAP kinases signaling (By similarity). Catalyzes 'Lys-63'-linked polyubiquitination of RIPK2 in parallel of XIAP (By similarity). . |
Accessions | ENST00000532970.5 ENST00000527230.2 A1L176 ENST00000618547.4 [Q8N2H9-3] E9PR85 ENST00000349459.10 [Q8N2H9-2] Q8N2H9 E9PQX6 ENST00000524466.5 [Q8N2H9-4] H0YEM6 ENST00000528752.1 ENST00000320740.12 [Q8N2H9-1] ENST00000526296.5 E9PI91 |